Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The reticuloendothelial system (RES), also known as the mononuclear phagocyte system (MPS), is a network of phagocytic cells distributed throughout the body. Key cell types include macrophages, monocytes, and dendritic cells, with major locations in the liver (Kupffer cells), spleen, lymph nodes, and bone marrow. The RES plays a critical role in immune defense through phagocytosis, antigen presentation, immune regulation, and the clearance of pathogens and cellular debris. Dysfunction of the RES is implicated in various diseases, including anemia, infections, inflammation, and storage diseases. Therapeutic interventions targeting the RES must consider potential safety concerns such as cytokine storm and immunosuppression.
N/A
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Reticuloendothelial System Phagocytic Cells (RES Phagocytic Cells).